The new study shows that one-third of the dose used for adults is effective for children between 5-12. Many parents are expecting the administration of vaccines for children especially for the ones attending school amid the surge of covid 19 cases. The total COVID-19 cases in children have jumped about 240% since July.
There is very little possibility of Children becoming severely ill from COVID-19 than adults. Children can act as a carrier of the virus and occasionally suffer serious disease and long-term consequences. The Food and Drug Administration and the Centers for Disease Control and Prevention will need to approve the vaccine before it becomes available to children, but government officials have promised to quickly review the data.
Dr Peter Marks said that the Authorization will come within a matter of weeks, not months. FDA is committed to going through those as quickly as they can. These data will not lay around when they come in. The Pfizer-BioNTech vaccine, called Comirnaty, is now fully approved for use in adults and older teens, though still authorized only for emergency use in 12- to 15-year-olds.
Albert Bourla, Pfizer chairman and the chief executive officer said that they are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the delta variant and the substantial threat it poses to children. The adult dose of the Pfizer-BioNTech vaccine is 30 micrograms, while the companies propose a 10 microgram dose in children ages 5 to 11. As in adults, the vaccine would be given to children in two shots, delivered at least three weeks apart.